{"gao_id": "GAO-20-262T", "published": "2019-12-10T12:00:00Z", "released": "2019-12-10T07:00:00Z", "summary": "More than 60% of drug manufacturers for the U.S. market are located overseas. The Food and Drug Administration inspects foreign and domestic drug manufacturers to ensure drug safety and effectiveness. Among other things, we testified that: The number of inspections of foreign drug manufacturers has declined since FY 2016, which FDA attributes in part to fewer inspectors and difficulty filling jobs abroad Most foreign inspections...", "title": "Drug Safety: Preliminary Findings Indicate Persistent Challenges with FDA Foreign Inspections", "topics": ["Foreign drug manufacturing", "Foreign drug inspection", "Generic drugs", "Compliance oversight", "Laws and regulations", "Manufacturing", "Prescription drugs", "Drugs", "Drug safety", "Health Care", "User fees"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-262t", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-262t-highlights.pdf"}, {"title": "Full Report (32 pages)", "url": "https://www.gao.gov/assets/gao-20-262t.pdf"}, {"title": "Accessible PDF (36 pages)", "url": "https://www.gao.gov/assets/710/705865.pdf"}]}